5β-Dihydrocortisol: Properties, Biosynthesis & Research Uses

5β-Dihydrocortisol is a hepatic metabolite of cortisol generated by the stereoselective reduction of the C4–C5 double bond by 5β-reductase (AKR1D1), representing an important intermediate in the glucocorticoid catabolic pathway.

Chemical Name

(5β)-Pregnane-3,20-dione-11β,17α,21-triol; 5β-Dihydrocortisol

Molecular Formula

C₂₁H₃₂O₅

Molecular Weight

368.47 g/mol

Key Biosynthetic Enzyme

5β-Reductase (AKR1D1)

Primary Tissue of Metabolism

Liver (hepatic steroid catabolism)

Precursor Molecule

Cortisol (hydrocortisone)

Aladdin SKU

D655606

Chemical Identity and Physical Properties

5β-Dihydrocortisol is a naturally occurring steroid and a primary hepatic metabolite of cortisol. Its IUPAC-based systematic name reflects the pregnane scaffold with characteristic hydroxyl groups at positions 11β, 17α, and 21, along with keto groups at C-3 and C-20. The defining structural feature is the cis-fusion of the A and B steroid rings, arising from the 5β-hydrogen configuration introduced by enzymatic reduction of the Δ4,5 double bond present in cortisol.

Key physical and chemical characteristics include a molecular formula of C₂₁H₃₂O₅ and a molecular weight of approximately 368.47 g/mol. The compound is a white to off-white crystalline solid. Like most polyhydroxylated steroids, it exhibits limited solubility in water but dissolves readily in organic solvents such as ethanol, methanol, and dimethyl sulfoxide (DMSO). Researchers handling 5β-Dihydrocortisol should store it at low temperature (typically −20 °C) under desiccated, inert conditions to prevent oxidative degradation of the sensitive hydroxyl and keto functionalities.

Biosynthesis and Metabolic Pathway

In humans, the inactivation and excretion of cortisol proceeds through a sequence of enzymatic transformations predominantly in the liver. The first and rate-limiting step in cortisol catabolism is the irreversible reduction of the C4–C5 double bond (the Δ4 double bond in ring A) by hepatic NADPH-dependent 5α- or 5β-reductases. When this reduction proceeds with 5β-stereoselectivity, mediated by the enzyme 5β-reductase (AKR1D1, aldo-keto reductase family 1 member D1), the product is 5β-dihydrocortisol.

5β-Dihydrocortisol is then further metabolized by 3α-hydroxysteroid dehydrogenase (3α-HSD, AKR1C enzymes) to yield tetrahydrocortisol (THF), which is subsequently conjugated with glucuronic acid in the liver to form a water-soluble glucuronide. This conjugate is efficiently excreted in the urine. Measurement of the 5β/5α metabolite ratio (THF/allo-THF) in urine is used clinically and experimentally as an indicator of relative 5β- versus 5α-reductase activity in an individual.

The overall flux through the 5β-reductase pathway is influenced by physiological state, thyroid hormone levels, age, sex, and various pathological conditions including liver disease. Dysregulation of this pathway has been linked to alterations in glucocorticoid sensitivity and metabolic syndromes.

Biological Significance and Research Context

Although 5β-Dihydrocortisol is itself considered largely biologically inactive as a glucocorticoid receptor (GR) agonist compared to cortisol, it occupies a pivotal position in the steroid metabolome. As a quantitatively significant urinary cortisol metabolite, its measurement provides a non-invasive readout of hepatic 5β-reductase activity and overall cortisol clearance. Alterations in its urinary levels have been studied in contexts including:

• Liver disease: Impaired hepatic metabolism alters the pattern of cortisol metabolites in urine.
• Obesity and metabolic syndrome: Altered 5β-reductase activity affects cortisol metabolism and has been associated with changes in whole-body glucocorticoid action.
• Thyroid disorders: Thyroid hormones regulate the expression and activity of hepatic 5β-reductase, influencing 5β-dihydrocortisol production.
• Cushing's syndrome and adrenal disorders: Excess cortisol production is reflected in elevated urinary metabolites including 5β-dihydrocortisol and its downstream products.

In the emerging field of steroid metabolomics, simultaneous quantification of multiple cortisol metabolites including 5β-dihydrocortisol using liquid chromatography-tandem mass spectrometry (LC-MS/MS) enables detailed phenotyping of the cortisol metabolome in health and disease.

Laboratory Applications and Handling Guidelines

5β-Dihydrocortisol (Aladdin SKU: D655606) is supplied as a research-grade reference standard suitable for a range of analytical and biochemical applications:

• Mass spectrometry reference standard: Used as an authentic reference compound for the development and validation of LC-MS/MS or GC-MS methods for urinary steroid profiling and cortisol metabolite quantification.
• Enzyme activity assays: Can serve as a substrate or product reference in in vitro assays measuring 5β-reductase (AKR1D1) or 3α-HSD activity.
• Steroid metabolomics: Inclusion of 5β-Dihydrocortisol as a calibrator or internal standard (when isotopically labeled analogs are unavailable) in metabolomics panels.
• Pharmacological studies: Investigation of glucocorticoid metabolism pathways in the context of drug interactions affecting hepatic steroid-metabolizing enzymes.

Handling recommendations: Dissolve in DMSO or ethanol for stock solutions; avoid prolonged exposure to light, moisture, and elevated temperatures. Confirm purity by HPLC before use in quantitative assays. Store at −20 °C under argon or nitrogen when possible. Repeated freeze-thaw cycles should be minimized by preparing single-use aliquots.

Frequently asked questions

What is 5β-Dihydrocortisol and how is it formed in the body?

5β-Dihydrocortisol is a major hepatic metabolite of cortisol produced when the enzyme 5β-reductase (AKR1D1) reduces the Δ4,5 double bond of cortisol in a stereospecific manner, creating a cis A/B ring junction. This reaction occurs primarily in the liver and represents the first committed step in glucocorticoid catabolism before further reduction to tetrahydrocortisol and urinary excretion as glucuronide conjugates.

How should 5β-Dihydrocortisol be stored and dissolved for laboratory use?

5β-Dihydrocortisol should be stored at −20 °C in a dry, dark environment under an inert atmosphere (nitrogen or argon) to prevent degradation. For laboratory use, it is best dissolved in DMSO or ethanol to prepare concentrated stock solutions. Aqueous dilutions can then be made from stock, though direct dissolution in water is not recommended due to limited aqueous solubility. Prepare single-use aliquots to avoid repeated freeze-thaw cycles.

What are the primary research applications of 5β-Dihydrocortisol as a reference standard?

As a reference standard, 5β-Dihydrocortisol is primarily used in the development and validation of LC-MS/MS and GC-MS methods for urinary steroid profiling. It is also employed in enzyme activity assays for 5β-reductase and 3α-hydroxysteroid dehydrogenase, in steroid metabolomics panels as a calibrator, and in pharmacological studies investigating hepatic glucocorticoid metabolism pathways.

How does measurement of 5β-Dihydrocortisol relate to clinical or physiological assessment?

Urinary 5β-dihydrocortisol and its downstream metabolite tetrahydrocortisol reflect hepatic 5β-reductase activity and the overall rate of cortisol catabolism. The ratio of 5β to 5α metabolites (THF/allo-THF) is used as a marker of relative 5β- versus 5α-reductase activity. Altered ratios have been studied in conditions such as liver disease, obesity, metabolic syndrome, thyroid disorders, and Cushing's syndrome.

References

1. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews. 2004;25(5):831-866. doi:10.1210/er.2003-0031
2. Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinology and Metabolism Clinics of North America. 2005;34(2):293-313. doi:10.1016/j.ecl.2005.01.002
3. Penning TM. Aldo-keto reductases and 5β-reductase in the metabolism of bile acids and steroids. Biochemical Journal. 2010 (Review).
4. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocrine Reviews. 2010;31(3):301-342. doi:10.1210/er.2009-0033

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.